Fig. 1From: A double-blind, randomized, multicenter, Italian study of frovatriptan versus rizatriptan for the acute treatment of migraineExample of preference scoring. For details on the contents of the preference questionnaire, please refer to Appendix 1 (Supplementary material)Back to article page